Gain Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $85.5M
- Price
- $2.00
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.26%
- Volume
- 277.5K
About
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Quick stats
Shares outstanding42.7M
Computed float40.9M
Float / shares95.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001819411
AI Summary
AI-generated1/13
majorbullishearnings
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported Q2 net loss of $0.11 per share, an improvement from $0.19 in the prior year, while R&D expenses decreased to $2.1 million.
The company achieved a key regulatory milestone with FDA IND authorization for rexaceract, positioning the asset to begin Phase 2 clinical development in Q3 2026 with durable biomarker responses observed in the Phase 1b extension.
Corporate updates include the promotion of Dr. Joanne Taylor to CSO and Terenzio Ignoni to COO, while pipeline asset GT-04686 advances toward IND-enabling studies.
Red flags
- Cash balance decreased from $20.8 million to $13.1 million in six months, indicating a burn rate that may require future financing